Wednesday, May 28, 2014
Auspex Pharmaceuticals, a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, has announced the expansion of its board of directors with the appointment of two new members: Lynn D. Bleil, former leader of McKinsey & Company’s West Coast Healthcare Practice and a leader of the worldwide Healthcare Practice; and R. Scott Greer, managing director of Numenor Ventures, and former founder, chairman and CEO of Abgenix. The total number of Auspex board members is increased to nine.
StemCells has launched its Alzheimer’s disease program, supported by the California Institute for Regenerative Medicine (CIRM). The goal is to file, within four years, an IND application with the FDA to evaluate the company’s proprietary HuCNS-SC product candidate (purified human neural stem cells) as a potential therapeutic in the treatment of Alzheimer’s disease.
The California Institute for Regenerative Medicine (CIRM), which awards grants and loans for stem cell research, has approved an award to StemCells, a cell-based therapeutics company based in Newark, Calif., for up to $20 million under CIRM’s Disease Team Therapy Development Award program (RFA 10-05).